(Q34155946)

31 July 2017

title

STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability (English)

1 reference

31 July 2017

12

Todd R Golub

1 reference

31 July 2017

11

Stuart L Schreiber

1 reference

31 July 2017

Tuoping Luo

1

1 reference

31 July 2017

Kristina Masson

2

1 reference

31 July 2017

Jacob D Jaffe

3

1 reference

31 July 2017

Whitney Silkworth

4

1 reference

31 July 2017

Nathan T Ross

5

1 reference

31 July 2017

Christina A Scherer

6

1 reference

31 July 2017

Claudia Scholl

7

1 reference

31 July 2017

Stefan Fröhling

8

1 reference

31 July 2017

Steven A Carr

9

1 reference

31 July 2017

Andrew M Stern

10

1 reference

31 July 2017

language of work or name

English

0 references

publication date

9 February 2012

1 reference

Proceedings of the National Academy of Sciences of the United States of America

31 July 2017

published in

1 reference

31 July 2017

volume

109

1 reference

31 July 2017

issue

8

1 reference

31 July 2017

page(s)

2860-2865

1 reference

describes a project that uses

31 July 2017

ImageJ

1 reference

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC3286931/fullTextXML

based on heuristic

inferred from PubMed Central ID database lookup

cites work

The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3286931

STK33 kinase activity is nonessential in KRAS-dependent cancer cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3286931

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3286931

Interaction with AKAP79 modifies the cellular pharmacology of PKC.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3286931

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3286931

A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3286931

Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3286931

Principles of cancer therapy: oncogene and non-oncogene addiction

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3286931

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3286931

The Serine/threonine kinase Stk33 exhibits autophosphorylation and phosphorylates the intermediate filament protein Vimentin

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3286931

Ras oncogenes: split personalities

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3286931

Accurate inclusion mass screening: a bridge from unbiased discovery to targeted assay development for biomarker verification

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3286931

A quantitative analysis of kinase inhibitor selectivity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3286931

Oncogene addiction: setting the stage for molecularly targeted cancer therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3286931

K-ras as a target for cancer therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3286931

Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: structural basis of selectivity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3286931

Targeting RAS signalling pathways in cancer therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3286931

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3286931

A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3286931

Integrating genetic approaches into the discovery of anticancer drugs

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3286931

Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle

5 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1073%2FPNAS.1120589109

Molecular targeted therapy of gastrointestinal stromal tumors.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1073%2FPNAS.1120589109

The case of the disappearing drug target

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1073%2FPNAS.1120589109

21 January 2018

Identifiers

DOI

10.1073/PNAS.1120589109

1 reference

31 July 2017

0 references

1 reference

31 July 2017

1 reference